Lynn Mitchell
Psychiatric/Mental Health · Riverhead, NYNPI 1457337404
Payments from drug & device makers
Across 212 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$671
- Teva Pharmaceuticals USA, Inc.$485
- Johnson & Johnson$325
- Lundbeck LLC$308
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$286
- plus $932 from 11 others
What the payments were for
- Food & beverage$4,01399%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 63 | $1,053 |
| Otsuka America Pharmaceutical, Inc. | 34 | $671 |
| Teva Pharmaceuticals USA, Inc. | 27 | $485 |
| Johnson & Johnson | 18 | $325 |
| Lundbeck LLC | 17 | $308 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $286 |
| E.r. Squibb & Sons, L.L.C. | 10 | $252 |
| Vanda Pharmaceuticals Inc. | 6 | $187 |
| Alkermes, Inc. | 7 | $145 |
| Axsome Therapeutics, Inc. | 5 | $109 |
| Neurocrine Biosciences, Inc. | 4 | $86 |
| Idorsia Pharmaceuticals US Inc | 2 | $45 |
| Neuronetics, Inc. | 2 | $28 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Braeburn Inc. | 1 | $18 |
How this compares
$4,060 in reported general payments places this provider in the 90th percentile of 2,385 psychiatric/mental health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 69 | $85,678 |
| Lurasidone Hcl | 16 | $16,575 |
| Clomipramine Hcl | 11 | $2,487 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $1,739 |
| Quetiapine Fumarate | 79 | $795 |
| Duloxetine Hcl | 11 | $794 |
| Olanzapine | 24 | $614 |
| Gabapentin | 61 | $544 |
| Methylphenidate Hcl | 19 | $461 |
| Aripiprazole | 17 | $390 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 32 | $360 |
| Hydroxyzine Hcl | 13 | $335 |
| Clonazepam | 41 | $258 |
| Bupropion XlBupropion Hcl | 38 | $246 |
| Lamotrigine | 46 | $245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $325 | $85,67869 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Riverhead
- Glenn HannDansville$1.3M
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
- Mary OlsonNew York$142K
- Elijah StevensBinghamton$131K
- Kayanna JonasFar Rockaway$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.